Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
361 questions in 74 reviews · Pain, Palliative and Supportive Care
current versionsNo studies 361 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Kappa‐opioid agonists vs placebo Quality of life ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Kappa‐opioid agonists vs placebo Patient satisfaction ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Kappa‐opioid agonists vs placebo Depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ondansetron vs placebo Quality of life ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ondansetron vs placebo Patient satisfaction ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ondansetron vs placebo Depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ GABA‐analogues vs placebo Quality of life ‐ not measured · health problem or population Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Montelukast vs placebo Quality of life ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Montelukast vs placebo Patient satisfaction ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Montelukast vs placebo depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Montelukast vs placebo Risk for at least one adverse event per participant ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Fish‐oil/omega‐3 fatty acids vs placebo Quality of life ‐ not measured · chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Fish‐oil/omega‐3 fatty acids vs placebo Patient satisfaction ‐ not measured · chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Fish‐oil/omega‐3 fatty acids vs placebo Depression ‐ not measured · chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ GABA‐analogues vs placebo Patient satisfaction ‐ not measured · health problem or population Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Fish‐oil/omega‐3 fatty acids vs placebo Adverse events ‐ not measured · chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Zinc sulphate vs placebo Quality of life ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Zinc sulphate vs placebo Patient satisfaction ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Zinc sulphate vs placebo Depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Cromolyn sodium vs placebo Quality of life ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Cromolyn sodium vs placebo Patient satisfaction ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Cromolyn sodium vs placebo Depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ GABA‐analogues vs placebo Depression ‐ not reported · health problem or population Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical capsaicin vs placebo Quality of life ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical capsaicin vs placebo Patient satisfaction ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical capsaicin vs placebo Depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Naltrexone vs placebo Quality of life ‐ not measured · patients with cholestatic pruritus (CP) Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Naltrexone vs placebo Patient satisfaction ‐ not measured · patients with cholestatic pruritus (CP) Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Naltrexone vs placebo Depression ‐ not measured · patients with cholestatic pruritus (CP) Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Rifampin/rifampicin vs placebo Quality of life ‐ not measured · patients with cholestatic pruritus (CP) Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Rifampin/rifampicin vs placebo Patient satisfaction ‐ not measured · patients with cholestatic pruritus (CP) Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Rifampin/rifampicin vs placebo Depression ‐ not measured · patients with cholestatic pruritus (CP) Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Flumecinol vs placebo Patient satisfaction ‐ not measured · patients with cholestatic pruritus (CP) Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Flumecinol vs placebo Depression ‐ not measured · patients with cholestatic pruritus (CP) Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Flumecinol vs placebo Risk for at least one adverse event per patient ‐ not measured · patients with cholestatic pruritus (CP) Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Gabapentin vs pregabalin Quality of life ‐ not reported · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Gabapentin vs pregabalin Patient satisfaction ‐ not reported · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Gabapentin vs pregabalin Depression ‐ not reported · patients with chronic kidney disease (CKD) pruritus Pharmacological interventions for pruritus in adult palliative care patients (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs placebo Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs paracetamol Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs morphine Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs morphine Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs morphine Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs morphine Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs morphine Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs ketorolac Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs placebo Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs ketorolac Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs ketorolac Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |
Ibuprofen vs ketorolac Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain Ibuprofen for acute postoperative pain in children (2024) · Cochrane | no estimate extracted | NR | No studies |